Robert Dolski
Director of Finance/CFO at AUTOLUS THERAPEUTICS PLC
Robert Dolski active positions
Companies | Position | Start | End |
---|---|---|---|
AUTOLUS THERAPEUTICS PLC | Director of Finance/CFO | 06/08/2023 | - |
Career history of Robert Dolski
Former positions of Robert Dolski
Companies | Position | Start | End |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 23/04/2020 | 17/05/2020 |
Director of Finance/CFO | 23/04/2020 | 17/05/2020 | |
Corporate Officer/Principal | 30/04/2019 | 23/04/2020 | |
MODERNA, INC. | Corporate Officer/Principal | 31/05/2016 | 30/04/2019 |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Corporate Officer/Principal | 30/11/2013 | 31/05/2016 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 31/03/2007 | 30/11/2012 |
CHECKMATE PHARMACEUTICALS, INC. | Director of Finance/CFO | 03/01/2021 | - |
Investor Relations Contact | 03/01/2021 | - |
Training of Robert Dolski
University of Pennsylvania | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
United States | 8 |
United Kingdom | 2 |
Operational
Corporate Officer/Principal | 4 |
Director of Finance/CFO | 3 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
MODERNA, INC. | Health Technology |
AUTOLUS THERAPEUTICS PLC | Health Technology |
Private companies | 4 |
---|---|
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Robert Dolski
- Experience